Conference Report

Update on Resistance to HBV and HCV Therapy: CCO Independent Conference Report on the 2008 Conference on Hepatitis B and C Virus Resistance to Antiviral Therapies

Source: CCO Independent Conference Coverage of the Conference on Hepatitis B and C Virus Resistance to Antiviral Therapies*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Update on Resistance to HBV and HCV Therapy: CCO Independent Conference Report on the 2008 Conference on Hepatitis B and C Virus Resistance to Antiviral Therapies


Faculty:

  • T. Jake Liang, MD
  • Jean-Michel Pawlotsky, MD, PhD

CME CREDIT INFORMATION

Release Date: 04/28/08

Expiration Date: 04/27/09


Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss new insights into the mechanisms by which hepatitis B virus (HBV) and hepatitis C virus (HCV) may develop resistance to antiviral therapy
  • Summarize recent findings related to cross-resistance between antiviral agents used in the treatment of patients with chronic HBV or HCV infection
  • Describe the latest data on clinical strategies that may minimize the risk of selection of drug-resistant HBV or HCV
  • Discuss new findings on approaches to the antiviral management of patients with drug-resistant HBV or HCV

Topics covered include:

  • Hepatitis B: Meeting Summary
  • Novel HBV Therapies
  • Resistance Rates Associated With HBV Therapies
  • Combination vs Monotherapy
  • Monitoring for Resistance
  • Management of Resistance
  • Mechanisms of Action of Currently Approved Agents for HCV Infection
  • Viral Dynamics in Nonresponse or Developing Resistance
  • New HCV Therapies: Protease Inhibitors
  • New HCV Therapies: Polymerase Inhibitors
  • STAT C Agents in HCV Treatment Failure
  • Future Treatment Strategies
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

This program is supported by an unrestricted educational grant from

Educational grants support only the CME-certified components of this program.